Qlife Holding AB (publ)

Stockholm Stock Exchange QLIFE.ST

Qlife Holding AB (publ) Shares (Diluted, Weighted) for the year ending December 31, 2023: 303,799

Qlife Holding AB (publ) Shares (Diluted, Weighted) is 303,799 for the year ending December 31, 2023, a 470.76% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.

Qlife Holding AB (publ) Shares (Diluted, Weighted) for the year ending December 31, 2022 was 53,227, a 17.83% change year over year.
Qlife Holding AB (publ) Shares (Diluted, Weighted) for the year ending December 31, 2021 was 45,174, a 21.03% change year over year.
Qlife Holding AB (publ) Shares (Diluted, Weighted) for the year ending December 31, 2020 was 37,325.

Key data

Date	Shares (Diluted, Weighted)	Revenue	Cost of Revenue	Gross Profit

Stockholm Stock Exchange: QLIFE.ST

Qlife Holding AB (publ)

CEO	Mr. Thomas Warthoe
IPO Date	March 2, 2020
Location	Sweden
Headquarters	Redaregatan 48
Employees	24
Sector	Health Care
Industries Pharmaceuticals Biotechnology Medical Instruments

Description

Qlife Holding AB (publ), a med-tech company, manufactures and sells in-vitro diagnostic analyzers and reagents. The company offers Egoo.Health Platform, an integrated platform with a measuring instrument with disposable capsules and software, where each capsule contains a test for a specific biomarker or virus. Its biomarkers include C-reactive protein home-testing capsule, PHE/Phenylalanine for PKU patients, and Sars-CoV-2/Influenza multiplex for virus/bacteria tests. The company was incorporated in 2019 and is based in Helsingborg, Sweden.

Key trends

Past 5 years